Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Quint-Fonsegrives – page 60

1 508 clinical trials in Quint-Fonsegrives, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Quint-Fonsegrives at a glance
1 508
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 508 trials in Quint-Fonsegrives

Open in trial search

Plasma cell myeloma

Not yet recruiting

A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

A study of mezigdomide, carfilzomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Assistance Publique Hopitaux De Paris

Colitis ulcerative

Not yet recruiting

A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Filgotinib
  • Sponsor:University Hospital Of Clermont-Ferrand

Axial spondyloarthritis

Not yet recruiting

A study comparing bimekizumab and adalimumab for treating chest pain in patients with active axial spondyloarthritis who do not respond well to non-steroidal anti-inflammatory drugs.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Rouen

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Post procedural complication+3

Not yet recruiting

Study of lidocaine hydrochloride to reduce side effects from pain medication in patients undergoing open liver surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of the effects of ibutamoren mesilate in prepubertal children with growth hormone deficiency

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ibutamoren Mesilate
  • Sponsor:Lumos Pharma LLC

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Pathios Therapeutics Limited

Plasma cell myeloma

Not yet recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Quint-Fonsegrives

What the registry says about research in the country

01 Urological Research

Extensive research focusing on bladder cancer treatments, including innovative therapies for both muscle-invasive and non-muscle-invasive cases. Studies also address prostate conditions, from benign hyperplasia to advanced cancer.

  • Advanced bladder cancer treatments
  • Prostate cancer therapy optimization
  • Kidney stone management

Novel approaches combine immunotherapy with targeted treatments to improve patient outcomes.

02 Oncology Studies

Comprehensive research into breast cancer treatments, particularly focusing on triple-negative and hormone receptor-positive variants. Studies evaluate new approaches in colon cancer management using circulating tumor DNA analysis.

  • Triple-negative breast cancer therapy
  • Colorectal cancer treatment
  • Lung cancer interventions

Investigations combine immunotherapy with traditional treatments for enhanced efficacy.

03 Specialized Medicine

Research addressing pulmonary conditions and specialized medical needs. Studies include evaluation of treatments for chronic obstructive pulmonary disease and migraine management in emergency settings.

  • COPD treatment optimization
  • Migraine therapy
  • Diabetic eye conditions

Focus on improving patient quality of life through innovative therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.